Product Description
Ciclopirox topical solution is used along with regular nail trimming to treat fungal infections of the fingernails and toenails (an infection that may cause nail discoloration, splitting and pain). Ciclopirox is in a class of medications called antifungals. It works by stopping the growth of nail fungus. (Sourced from: https://medlineplus.gov/druginfo/meds/a604021.html)
Mechanisms of Action: ATPase Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Stiefel Laboratories
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Dermatitis, Seborrheic
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ATL001-PI-CEP | P1 |
Completed |
Healthy Volunteers |
2024-04-08 |
|
| CTR20132646 | P3 |
Recruiting |
Dermatitis, Seborrheic |
None |